Product
MRI contrast-enhancing preparations
1 clinical trial
1 indication
Indication
Multiple SclerosisClinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple SclerosisStatus: Active (not recruiting), Estimated PCD: 2022-09-21